ATE319683T1 - Selektive 5-ht 6-rezeptor-liganden - Google Patents

Selektive 5-ht 6-rezeptor-liganden

Info

Publication number
ATE319683T1
ATE319683T1 AT99967248T AT99967248T ATE319683T1 AT E319683 T1 ATE319683 T1 AT E319683T1 AT 99967248 T AT99967248 T AT 99967248T AT 99967248 T AT99967248 T AT 99967248T AT E319683 T1 ATE319683 T1 AT E319683T1
Authority
AT
Austria
Prior art keywords
selective
receptor ligands
receptors
compounds
treatment
Prior art date
Application number
AT99967248T
Other languages
English (en)
Inventor
Richard A Glennon
Bryan L Roth
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Application granted granted Critical
Publication of ATE319683T1 publication Critical patent/ATE319683T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Escalators And Moving Walkways (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Control Of High-Frequency Heating Circuits (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Conductive Materials (AREA)
AT99967248T 1998-12-11 1999-12-10 Selektive 5-ht 6-rezeptor-liganden ATE319683T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11178798P 1998-12-11 1998-12-11

Publications (1)

Publication Number Publication Date
ATE319683T1 true ATE319683T1 (de) 2006-03-15

Family

ID=22340454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967248T ATE319683T1 (de) 1998-12-11 1999-12-10 Selektive 5-ht 6-rezeptor-liganden

Country Status (10)

Country Link
EP (1) EP1149078B1 (de)
AT (1) ATE319683T1 (de)
AU (1) AU767009B2 (de)
CA (1) CA2353962C (de)
DE (1) DE69930308T2 (de)
DK (1) DK1149078T3 (de)
ES (1) ES2260958T3 (de)
MX (1) MXPA01005905A (de)
PT (1) PT1149078E (de)
WO (1) WO2000034242A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
EP1859798B1 (de) * 2001-03-29 2015-12-30 Eli Lilly And Company N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
CZ305838B6 (cs) * 2001-03-29 2016-04-06 Eli Lilly And Company N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
KR20090019894A (ko) 2001-06-11 2009-02-25 바이오비트럼 에이비(피유비엘) 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형 당뇨병 치료용 약제로서의 이들의 사용 방법
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
EP1897881A3 (de) 2002-06-20 2009-03-18 Biovitrum AB (publ) Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen
BR0312176A (pt) * 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
AU2003292510B2 (en) 2002-12-18 2009-04-23 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity
HRP20130638T1 (en) 2003-06-26 2013-08-31 Takeda Pharmaceutical Company Limited Cannabinoid receptor modulator
CA2532382A1 (en) * 2003-07-31 2005-02-10 Wyeth N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
EP1807427A2 (de) 2004-11-01 2007-07-18 Wyeth Substituierte indolizine und derivate als zns-wirkstoffe
US7582767B2 (en) 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
PL1948166T3 (pl) * 2005-10-19 2011-04-29 Suven Life Sciences Ltd Pochodne karbazolu jako ligandy czynnościowe 5-HT6
EP2134714A1 (de) 2007-03-13 2009-12-23 Biovitrum AB (publ) Tricyclische isochinolinderivate zur behandlung von obesitas
WO2009073118A1 (en) * 2007-12-04 2009-06-11 Merck & Co., Inc. Tryptamine sulfonamides as 5-ht6 antagonists
EP2103596A1 (de) 2008-03-18 2009-09-23 Laboratorios Del. Dr. Esteve, S.A. Verfahren zur Herstellung von N-(Phenylethyl)-Anilinsalzen und deren Solvate zur nützlichen Verwendung als Serotonin-5-HT6-Antagonisten
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
FR2961097B1 (fr) * 2010-06-09 2012-07-13 Oreal Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
FR2961095B1 (fr) * 2010-06-09 2012-06-15 Oreal Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
EP4259157A4 (de) * 2020-12-09 2024-07-10 Caamtech, Inc. Dialkyltryptamine und ihre therapeutischen verwendungen
CN118715204A (zh) * 2021-12-24 2024-09-27 普赛洛私人有限公司 化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
GB8416724D0 (en) * 1984-06-30 1984-08-01 Sorbio Sa Lab Active compounds

Also Published As

Publication number Publication date
CA2353962C (en) 2009-09-29
MXPA01005905A (es) 2002-09-18
CA2353962A1 (en) 2000-06-15
AU2356200A (en) 2000-06-26
DE69930308T2 (de) 2006-11-30
AU767009B2 (en) 2003-10-30
EP1149078A1 (de) 2001-10-31
EP1149078A4 (de) 2003-01-29
WO2000034242A1 (en) 2000-06-15
EP1149078B1 (de) 2006-03-08
ES2260958T3 (es) 2006-11-01
PT1149078E (pt) 2006-07-31
DE69930308D1 (de) 2006-05-04
DK1149078T3 (da) 2006-07-10

Similar Documents

Publication Publication Date Title
DE69930308D1 (de) Selektive 5-ht 6-rezeptor-liganden
DK1588706T3 (da) Valsartantablet
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
EA200200560A1 (ru) Полициклоалкилпурины в качестве антагонистов аденозиновых рецепторов
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
EA200000299A1 (ru) Лекарства
FR2799124B1 (fr) Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
EA199900912A1 (ru) Фармацевтические средства
MXPA04006555A (es) Piridazinodionas-3,4-disustituidas como antagonistas de receptor de quimiocina cxc.
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
EE9900595A (et) Spetsiifilise 5-HT 2A-retseptori antagonisti kasutamine une hingamishäirete raviks kasulike ravimite valmistamiseks
TR200200544T2 (tr) Bağlı pirolkarboksamitler: gaba beyin alıcı ligantları
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
PT883401E (pt) Antagonista do receptor at1 para estimulacao da apoptose
WO2002017922A8 (en) Bridged nicotine compounds for use in the treatment of cns pathologies
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
TNSN00178A1 (en) Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands
ITMI940223A0 (it) N-acetiltriptamine-2-sostituite, antagoniste ad elevata affinita' del recettore della melatonina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1149078

Country of ref document: EP

REN Ceased due to non-payment of the annual fee